Compare Todays Range 0.29 0.32 50-Day Range 0. The firm is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications and TYME-18 for the treatment of solid tumors. Tyme Technologies (TYME) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Its preclinical pipeline programs SM-88i, TYME-18, TYME-T and TYME-19. Tyme Technologies Inc (TYME) has a Smart Score of N/A based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity. TYME is focused on evaluating its preclinical pipeline of novel CMBT programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. TYME's lead drug product, SM-88, is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. The company is headquartered in Bedminster, New Jersey and currently employs 13 full-time employees. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. News Summary TYME US90238J1034 TYME TECHNOLOGIES, INC. Other terms include any time money, cashline, tyme machine. : Stock Market News and Information TYME US90238J1034 MarketScreener Homepage Equities United States Nasdaq Tyme Technologies, Inc. Prior results do not guarantee similar outcomes.Tyme Technologies, Inc. own CVV credit Find Unicredit Bankomat stock photos and editorial news pictures from. It has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as.
#TYME STOCK NEWS FREE#
For more information, please feel free to call us. TYME Technologies Inc (NASDAQ: TYME) has decided to explore potential strategic options. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. If you own TYME common stock and wish to obtain additional information, please contact Guri Ademi either at toll-free: 86, or. Tyme Technologies Inc (TYME) Price Targets From Analysts The tables below show the price targets and recommendations analysts covering TYME. We are investigating the conduct of TYME's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for TYME. (NYSE: C ): 63.48 Number of Hedge Funds: 95 (2020Q4) Number of Hedge Funds: 91 (2020Q3) Total Dollar Amount of Long Hedge Fund Positions: 6.94 billion Percent of Hedge Funds with.
TYME insiders will receive substantial benefits as part of change of control arrangements. Tyme Technologies Inc - Company Profile and News - Bloomberg Markets Bloomberg Terminal Demo Request Bloomberg Connecting decision makers to a dynamic network of information, people and ideas.
The transaction agreement unreasonably limits competing bids for TYME by imposing a significant penalty if TYME accepts a superior bid. A Motley Fool article went on to explain in detail the misleading picture as to the efficacy of SM-88 on pancreatic cancer. The actual number of shares to be issued in the merger and the exchange ratio will be subject to adjustment based on the amount of TYME's net cash at closing and the number of TYME shares outstanding at closing. There is no cost or obligation to you.Īdemi LLP alleges TYME's financial outlook and prospects are excellent and yet TYME holders will receive only approximately 0.4312 shares of Syros common stock for each share of TYME common stock. On December 22, 2021, the Company received notice from The Nasdaq Stock Market ('Nasdaq') that the closing bid price for our common stock had been below 1.
#TYME STOCK NEWS HOW TO#
AdemiLogo (PRNewsfoto/Ademi LLP) (PRNewswire)Ĭlick here to learn how to join the action: or call Guri Ademi toll-free at 86.
0 kommentar(er)
